CommercialCoverageHigh impact
Urine Drug Testing 2.02.50
Excellus BlueCross BlueShield·Pain Management, Family Medicine, Internal Medicine +1 more·Lab Tests (pathology)
Effective date
Oct 16, 2025
We identified it
Jun 20, 2026
Summary
Excellus BlueCross BlueShield updated their urine drug testing policy effective October 16, 2025, establishing specific criteria for when presumptive and definitive urine drug testing is medically appropriate for pain management and substance use treatment. The policy requires clinical documentation, informed consent, and specific testing frequencies based on patient risk levels and treatment phases.
Action Required
By October 16, 2025: Billing team must ensure all urine drug testing claims include proper documentation of clinical assessment, informed consent, and rationale for testing frequency. Providers must document patient risk levels and consecutive days of abstinence to justify testing frequency limits (1-3 tests per week for early treatment, reduced frequency for stable patients). Update encounter forms to include required elements: clinical assessment completion, test interpretation knowledge, and care plan impact. Claims exceeding frequency limits without clinical documentation will be denied.